330 related articles for article (PubMed ID: 28830266)
21. The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study.
Ibrahim NE; Januzzi JL
Curr Heart Fail Rep; 2018 Apr; 15(2):37-43. PubMed ID: 29468530
[TBL] [Abstract][Full Text] [Related]
22. Biomarkers as a guide of medical treatment in cardiovascular diseases.
Vavuranakis M; Kariori MG; Kalogeras KI; Vrachatis DA; Moldovan C; Tousoulis D; Stefanadis C
Curr Med Chem; 2012; 19(16):2485-96. PubMed ID: 22489719
[TBL] [Abstract][Full Text] [Related]
23. Biomarkers for heart failure: small molecules with high clinical relevance.
Magnussen C; Blankenberg S
J Intern Med; 2018 Jun; 283(6):530-543. PubMed ID: 29682806
[TBL] [Abstract][Full Text] [Related]
24. Biomarker-based risk prediction in the community.
AbouEzzeddine OF; McKie PM; Scott CG; Rodeheffer RJ; Chen HH; Michael Felker G; Jaffe AS; Burnett JC; Redfield MM
Eur J Heart Fail; 2016 Nov; 18(11):1342-1350. PubMed ID: 27813304
[TBL] [Abstract][Full Text] [Related]
25. B-type natriuretic peptide in heart failure.
Moe GW
Curr Opin Cardiol; 2006 May; 21(3):208-14. PubMed ID: 16601459
[TBL] [Abstract][Full Text] [Related]
26. Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society.
Tsutsui H; Albert NM; Coats AJS; Anker SD; Bayes-Genis A; Butler J; Chioncel O; Defilippi CR; Drazner MH; Felker GM; Filippatos G; Fiuzat M; Ide T; Januzzi JL; Kinugawa K; Kuwahara K; Matsue Y; Mentz RJ; Metra M; Pandey A; Rosano G; Saito Y; Sakata Y; Sato N; Seferovic PM; Teerlink J; Yamamoto K; Yoshimura M
J Card Fail; 2023 May; 29(5):787-804. PubMed ID: 37117140
[TBL] [Abstract][Full Text] [Related]
27. Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
Bhardwaj A; Rehman SU; Mohammed A; Baggish AL; Moore SA; Januzzi JL
Am Heart J; 2010 Apr; 159(4):532-538.e1. PubMed ID: 20362709
[TBL] [Abstract][Full Text] [Related]
28. The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure.
Motiwala SR; Januzzi JL
Clin Pharmacol Ther; 2013 Jan; 93(1):57-67. PubMed ID: 23187878
[TBL] [Abstract][Full Text] [Related]
29. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
[TBL] [Abstract][Full Text] [Related]
30. Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH.
Meijers WC; de Boer RA; van Veldhuisen DJ; Jaarsma T; Hillege HL; Maisel AS; Di Somma S; Voors AA; Peacock WF
Eur J Heart Fail; 2015 Dec; 17(12):1271-82. PubMed ID: 26466857
[TBL] [Abstract][Full Text] [Related]
31. Natriuretic peptides and heart failure in the patient with chronic kidney disease: a review of current evidence.
Dhar S; Pressman GS; Subramanian S; Kaul S; Gollamudi S; Bloom EJ; Figueredo VM
Postgrad Med J; 2009 Jun; 85(1004):299-302. PubMed ID: 19528304
[TBL] [Abstract][Full Text] [Related]
32. [Clinical significance of natriuretic peptides in the differential diagnosis of dyspnea].
Špác J
Vnitr Lek; 2016; 62(7-8):640-5. PubMed ID: 27627091
[TBL] [Abstract][Full Text] [Related]
33. [Biomarkers in heart failure: BNP and NT-proBNP].
Ho CC; Liu CC
Hu Li Za Zhi; 2009 Oct; 56(5):16-22. PubMed ID: 19760573
[TBL] [Abstract][Full Text] [Related]
34. The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use.
Januzzi JL
Arch Cardiovasc Dis; 2012 Jan; 105(1):40-50. PubMed ID: 22369917
[TBL] [Abstract][Full Text] [Related]
35. Worsening Renal Function during Management for Chronic Heart Failure with Reduced Ejection Fraction: Results From the Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
Ibrahim NE; Gaggin HK; Rabideau DJ; Gandhi PU; Mallick A; Januzzi JL
J Card Fail; 2017 Feb; 23(2):121-130. PubMed ID: 27469482
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
Zile MR; Claggett BL; Prescott MF; McMurray JJ; Packer M; Rouleau JL; Swedberg K; Desai AS; Gong J; Shi VC; Solomon SD
J Am Coll Cardiol; 2016 Dec; 68(22):2425-2436. PubMed ID: 27908347
[TBL] [Abstract][Full Text] [Related]
37. ST2 pathogenetic profile in ambulatory heart failure patients.
Bayes-Genis A; Januzzi JL; Gaggin HK; de Antonio M; Motiwala SR; Zamora E; Galán A; Domingo M; Urrutia A; Lupón J
J Card Fail; 2015 Apr; 21(4):355-61. PubMed ID: 25451702
[TBL] [Abstract][Full Text] [Related]
38. Natriuretic peptides and NGAL in heart failure: does a link exist?
Palazzuoli A; Beltrami M; Pellegrini M; Nuti R
Clin Chim Acta; 2012 Nov; 413(23-24):1832-8. PubMed ID: 22820397
[TBL] [Abstract][Full Text] [Related]
39. Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure.
Balion C; Santaguida PL; Hill S; Worster A; McQueen M; Oremus M; McKelvie R; Booker L; Fagbemi J; Reichert S; Raina P
Evid Rep Technol Assess (Full Rep); 2006 Sep; (142):1-147. PubMed ID: 17764210
[TBL] [Abstract][Full Text] [Related]
40. Rationale and design of the ICON-RELOADED study: International Collaborative of N-terminal pro-B-type Natriuretic Peptide Re-evaluation of Acute Diagnostic Cut-Offs in the Emergency Department.
Gaggin HK; Chen-Tournoux AA; Christenson RH; Doros G; Hollander JE; Levy PD; Nagurney JT; Nowak RM; Pang PS; Patel D; Peacock WF; Walters EL; Januzzi JL;
Am Heart J; 2017 Oct; 192():26-37. PubMed ID: 28938961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
